



VENUE



PARANIMF DE LA FACULTAT DE MEDICINA DE LA UB

Carrer de Casanova, 143, 08036 Barcelona



TECHNICAL SECRETARY

Enric Clarella - L'Acadèmia

Departament d'Activitats i Congressos

C/ Major de Can Caralleu, 1-7

08017 Barcelona

Tel. 93 203 18 52 - Fax 93 212 35 69

enricclarella@academia.cat

Registration: lourdescampanya@academia.cat



SPONSORS



Bristol-Myers Squibb




BTG



IPSEN
Innovation for patient care




THE 2019 BCLC UPDATE IN LIVER CANCER



November 28th-29th 2019

PARANIMF FACULTAT DE MEDICINA DE LA UB





Dear friends and colleagues,

It is our pleasure to invite you to a novel event at the **Barcelona Clinic Liver Cancer (BCLC)**. The meeting is designed to be very interactive, as it is structured to prime the debate around the most recent data and controversies in the field of liver cancer. Thus, rather than crafting a conventional program with formal presentations describing already published information, we have designed the content around well defined clinical situations where management decisions have to be taken, and where robust research is eagerly awaited.

As well known, in the last decade we have witnessed a major change in our diagnostic capacity and how to better stratify patients according to prognosis and treatment recommendation. In addition, several new systemic therapies have been evaluated and, now, we enjoy the availability of several systemic options that have a positive impact in the survival of our patients. All investigations, irrespective of their positive or negative outcome, provide opportunities to increase our knowledge and incorporate new concepts that should drive both, clinical decision-making and trial design and analysis. Adjuvant trials for early stage disease and combination trials for advanced stages are now being evaluated in different development phases. Sure some will be successful and offer further survival benefits but again, negative results will provide insight for further research.

We hope that you will find the program and the design appealing to join us next November in Barcelona.

Jordi Bruix on behalf of the BCLC



Organizer | BCLC group. Hospital Clínic.
University of Barcelona.
IDIBAPS. CIBEREHD

Location | Paranimf Hall
School of Medicine
University of Barcelona.

TIMETABLE

The event is organized in sessions devoted to the debate of specific clinical scenarios. Speakers will comment about the most controversial issues and expose a minor number of slides just to support concepts.

A list of key references will be provided to gather all relevant information that may be discussed. This will be sent by e-mail to all participants after the completion of the meeting.

November 28th

🕒 13:00 - 13:50

ACCREDITATION AND MATERIAL DELIVERY

🕒 13:50 - 14:00

OPENING

A. Castells. Medical Director of Hospital Clinic

🕒 14:00 - 16:00

CONTROVERSIES IN DIAGNOSIS AND STAGING OF HCC

- Screening strategies
- LIRADS vs AASLD/EASL criteria
- Tumor markers
- Molecular signatures for diagnosis and prognosis
- Usefulness of PET
- Overdiagnosis and overtreatment

Chair: C. Ayuso

Participants: J.C. Nault, A. Forner, M.A. Díaz, L. Boix, I. Bargellini

Case presentation: M. Sanduzzi, M.A. García-Criado

☕ 16:00 - 16:30: Coffee break

🕒 16:30 - 18:30

MANAGEMENT OF BCLC 0 AND A PATIENTS

- Definitions of BCLC vs EASL guidelines
- Who should and who should not be transplanted, operated or ablated
- Priority strategies for LT
- Live donation: same criteria as for CDLT?
- Role of bridging and downstaging
- Prevention of recurrence after transplant, resection or ablation
- Benefits and risks of antiviral therapy

Chair: A. Forner

Participants: G. Sapisochin, J. Ferrer, P. Majno, L. Bianchi, J. Ricke, P. Galle

Case presentation: S. Muñoz, A. Darnell

🕒 18:30 End of day 1

November 29th

🕒 08:30 - 10:30

LOCOREGIONAL APPROACH IN HCC PATIENTS

- Any novelty in starting and stopping?
- Clinical and technical value of new TACE materials
- Novelties in TARE
- Is there a niche for TARE?
- Adjuvancy in TACE: failures and hopes

Chair: J. Bruix

Participants: M. Reig, M. Burrel, I. Bargellini, S. Bhorrie, J. Ricke, J. Rimola

Case presentation: M. Sanduzzi, M. Barrufet

🕒 10:30 - 11:00

Special lecture 1

CRITERIA FOR RESPONSE ASSESSMENT AND PREDICTION OF SURVIVAL BENEFIT

J. Bruix

☕ 11:00 - 11:30 Coffee Break

🕒 11:30 - 13:30

SYSTEMIC THERAPY

- How do trial results translate into clinical practice?
- Definition and drug priority for candidates for 1st, 2nd and 3rd line
- Analysis of adverse events detection and management
- Hopes and facts in immunotherapy
- Enrichment by signatures? By liquid biopsy?

Chair: M Reig

Participants: M. Reig, J.C. Nault, P. Galle, B. Sangro, J. Rimola,

A. Darnell, L. Rimassa

Case presentation: L. Fonseca, E. Belmonte

🕒 13:30 - 14:00

Special lecture 2

INTRAHEPATIC CHOLANGIOCARCINOMA: THE EMERGING ENTITY

L. Rimassa

🕒 14:00 Closure of the meeting